|View printer-friendly version|
Portola Pharmaceuticals Supports 2018 World Thrombosis Day Campaign to Raise Awareness of Blood Clots as an Urgent and Growing Health Crisis
Atrial fibrillation (AFib) and venous thromboembolism (VTE) are two major causes of thrombosis that affect millions of people worldwide. AFib, or arrhythmia, is a common type of irregular heartbeat that can lead to a clot forming in the chamber of the heart and traveling to the brain. Although less common than VTE, AFib increases the individual risk of stroke and accounts for approximately 15 percent of the 15 million strokes that occur worldwide every year.
VTE refers collectively to deep vein thrombosis (DVT), a clot in a deep vein, usually in the leg, groin or arm; or a pulmonary embolism (PE), an often-fatal condition that occurs when a DVT breaks free from a vein wall and travels to the lungs, blocking some or all of the blood supply. In
“VTE is the leading cause of preventable hospital death – ahead of pneumonia and infection – with more than half of all VTE cases occurring within the first 40 days following hospital admission,” said
“Thrombosis is the leading cause of the world’s top three cardiovascular killers – heart attack, stroke and VTE,” said
About World Thrombosis Day
Now in its fifth year, World Thrombosis Day is a global movement observed annually on
World Thrombosis Day’s mission supports the
About the ISTH
Founded in 1969, the
Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, and Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers.